Affordable Access

Visual acuity and intraocular pressure after high-dose intravitreal triamcinolone acetonide in selected ocular diseases.

Authors
  • Jonas, J B
  • Schlichtenbrede, F
Type
Published Article
Journal
Eye (London, England)
Publication Date
Jul 01, 2008
Volume
22
Issue
7
Pages
869–873
Identifiers
PMID: 17304257
Source
Medline
License
Unknown

Abstract

Improvement in vision after intravitreal triamcinolone monotherapy is highest in non-ischaemic diseases with an intraretinal macular oedema such as pseudophakic cystoid macular oedema; it is lower in partially ischaemic diseases with intraretinal macular oedema such as diabetic macular oedema or retinal vein occlusions; and it is lowest in diseases with a primarily subretinal location of the disease such as exudative age-related macular degeneration. For the latter diseases, intravitreal triamcinolone monotherapy is, therefore, no longer up-to-date, particularly with the upcoming intravitreal application of vascular endothelial growth factor blocking drugs. For diseases with intraretinal oedema, the rule of thumb may be that intravitreal triamcinolone increases vision as much as retinal ischaemia and tissue destruction by the underlying disease allow it. The rise in intraocular pressure is higher in relatively young patients with uveitis than in elderly patients with other reasons for macular oedema.

Report this publication

Statistics

Seen <100 times